2.2. Study Design
The trial period was 13 weeks, including 1-week baseline monitoring and a 12-week intervention. First-pass eligibility testing was performed by email/phone with a screening questionnaire according to the inclusion/exclusion criteria detailed above. Participants who appeared eligible were invited to attend a screening visit at South Australian Health and Medical Research Institute. Participants had the research protocol explained and provided the written consent form to participate in the study. Weight, height, and blood pressure were measured. A fasting blood sample was collected to evaluate liver (liver enzymes >3 times upper limit considered normal) and kidney (creatinine and estimated glomerular filtration rate <60 mL/min/1.73 m